Education
About Us
Working with TipRanks
Follow Us
Rapid Micro Biosystems, Inc. Class A (RPID)
:RPID
RPID Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.58 - $4.04
Previous CloseN/A
Volume19.55K
Average Volume (3M)89.03K
Market Cap
$156.92M
Enterprise Value$28.88M
Total Cash (Recent Filing)$41.67M
Total Debt (Recent Filing)$5.88M
Price to Earnings (P/E)―
Beta0.72
Next Earnings
Aug 01, 2025EPS Estimate
-0.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.26
Shares Outstanding39,332,172
10 Day Avg. Volume92,137
30 Day Avg. Volume89,028
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)0.29
Price to Sales (P/S)0.00
P/FCF Ratio-0.73
Enterprise Value/Market Cap0.18
Enterprise Value/Revenue0.27
Enterprise Value/Gross Profit8.04
Enterprise Value/Ebitda-0.15
Forecast
1Y Price Target
$8.00Price Target Upside123.46% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering0
Rapid Micro Biosystems News
PremiumCompany Announcements
Rapid Micro Biosystems CEO Diagnosed with Lymphoma
PremiumCompany Announcements
Rapid Micro Biosystems Board Resignation and Elections
PremiumCompany Announcements
Rapid Micro Biosystems Reports Strong Q1 2025 Growth
PremiumCompany Announcements
Rapid Micro Biosystems’ Earnings Call Highlights Growth Amid Challenges
Bulls Say, Bears Say
Bulls Say
Market AcceptanceRPID's system has 164 installations and is used by 70% of the top 20 biopharmas and Lonza, validating its acceptance and effectiveness in the market.
Product AdoptionRapid Micro Bio's Microbial Growth Direct System is changing the paradigm in biological manufacturing quality control by being more accurate and providing digital results faster than traditional methods.
Revenue GrowthThe company is gaining wide adoption in the biopharmaceutical industry, with a 28% revenue growth from 2022-2024, leading to increased top-line visibility and improving margins.
Bears Say
Dependence On Key CustomersThe Q3 was driven by a multi-system Growth Direct instrument order from an existing top 20 global pharma customer, raising questions about dependency on a few large clients for revenue.
Revenue ExpectationsAlthough Q3 revs of $7.6M hit a record-high for the company, there may be concerns about sustaining this level of revenue growth.
Options Prices
Currently, No data available
---
Ownership Overview
4.88% Insiders
2.66% Mutual Funds
30.59% Other Institutional Investors
59.55% Public Companies and Individual Investors
RPID FAQ
What was Rapid Micro Biosystems, Inc. Class A’s price range in the past 12 months?
Rapid Micro Biosystems, Inc. Class A lowest stock price was $0.58 and its highest was $4.04 in the past 12 months.
What is Rapid Micro Biosystems, Inc. Class A’s market cap?
Rapid Micro Biosystems, Inc. Class A’s market cap is $156.92M.
When is Rapid Micro Biosystems, Inc. Class A’s upcoming earnings report date?
Rapid Micro Biosystems, Inc. Class A’s upcoming earnings report date is Aug 01, 2025 which is in 32 days.
How were Rapid Micro Biosystems, Inc. Class A’s earnings last quarter?
Rapid Micro Biosystems, Inc. Class A released its earnings results on May 09, 2025. The company reported -$0.26 earnings per share for the quarter, beating the consensus estimate of -$0.27 by $0.01.
Is Rapid Micro Biosystems, Inc. Class A overvalued?
According to Wall Street analysts Rapid Micro Biosystems, Inc. Class A’s price is currently Undervalued.
Does Rapid Micro Biosystems, Inc. Class A pay dividends?
Rapid Micro Biosystems, Inc. Class A does not currently pay dividends.
What is Rapid Micro Biosystems, Inc. Class A’s EPS estimate?
Rapid Micro Biosystems, Inc. Class A’s EPS estimate is -0.26.
How many shares outstanding does Rapid Micro Biosystems, Inc. Class A have?
Rapid Micro Biosystems, Inc. Class A has 39,332,172 shares outstanding.
What happened to Rapid Micro Biosystems, Inc. Class A’s price movement after its last earnings report?
Rapid Micro Biosystems, Inc. Class A reported an EPS of -$0.26 in its last earnings report, beating expectations of -$0.27. Following the earnings report the stock price went up 25.714%.
Which hedge fund is a major shareholder of Rapid Micro Biosystems, Inc. Class A?
Currently, no hedge funds are holding shares in RPID
Rapid Micro Biosystems Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.00 (123.46% Upside)
$8.00 (123.46% Upside)
Blogger Sentiment
Bullish
RPID Sentiment 70%
Sector Average 71%
Sector Average 71%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 4.8%
Last 30 Days ▼ 10.8%
Last 30 Days ▼ 10.8%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
415.85%
12-Months-Change
Fundamentals
Return on Equity
-52.30%
Trailing 12-Months
Asset Growth
-33.11%
Trailing 12-Months
Company Description
Rapid Micro Biosystems, Inc. Class A
Rapid Micro Biosystems, Inc., a life sciences technology company, provides products for the detection of microbial contamination in the manufacture of pharmaceutical, medical devices, and personal care products in North America, Europe, and Asia. The company offers Growth Direct platform, which includes Growth Direct system, proprietary consumables, lab information management system connection software, and comprehensive customer support and validation services. Its platform automates and modernizes the manual microbial quality control (MQC) testing workflows for therapeutic modalities, such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company also provides installation and verification, technical training, and support services. Its solutions are used in environmental monitoring, water testing, bioburden, and sterility release testing applications. The company was formerly known as Genomic Profiling Systems, Inc. and changed its name to Rapid Micro Biosystems, Inc. in January 2007. Rapid Micro Biosystems, Inc. was incorporated in 2006 and is headquartered in Lowell, Massachusetts.
RPID Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call emphasized strong revenue growth and significant improvements in service revenue and gross margins. However, challenges remain with high operating expenses, negative product margins, and a substantial net loss. The collaboration with MilliporeSigma and customer demand for GrowthDirect provide a positive outlook, though macroeconomic uncertainties persist.Read More>